--- title: "U.S. stock market midday update: Decoy Therapeutics down 8.54%, volume increased, sector volatility intensified" type: "News" locale: "en" url: "https://longbridge.com/en/news/292350396.md" description: "Decoy Therapeutics fell 8.54%; AbbVie fell 1.06%, with a trading volume of USD 718 million; Alibaba's Arm Pharmaceuticals fell 4.21%, with a trading volume of USD 496 million; Ionis Pharmaceuticals fell 8.80%, with a trading volume of USD 478 million; Amgen fell 0.38%, with a market capitalization of USD 195.5 billion" datetime: "2026-07-10T18:52:38.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292350396.md) - [en](https://longbridge.com/en/news/292350396.md) - [zh-HK](https://longbridge.com/zh-HK/news/292350396.md) generator: "portal-rs" --- # U.S. stock market midday update: Decoy Therapeutics down 8.54%, volume increased, sector volatility intensified **U.S. Stock Market Midday Update** Decoy Therapeutics, down 8.54%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** AbbVie down 1.06%. Based on recent key news: 1. On July 9, Morgan Stanley raised AbbVie's target price to $279, expecting the company's second-quarter revenue to exceed market consensus and guidance, but earnings per share slightly below market forecasts, leading to stock price volatility. 2. On July 10, JP Morgan raised AbbVie's target price from $260 to $280, maintaining an "Overweight" rating, further driving stock price volatility. 3. On July 8, the European Commission approved the label expansion of AbbVie's blood cancer treatment Tepkinly, co-developed with Genmab, covering 27 EU member states and other regions, enhancing market confidence. The biopharmaceutical industry is expected to be driven by fundamental factors in the second half of the year. Alnylam Pharmaceuticals down 4.21%. Based on recent news: 1. On July 9, AstraZeneca's gene-silencing drug trial failed, leading to a rise in the stock prices of Alnylam's competitors. AstraZeneca's drug failed to meet the primary goal of reducing cardiovascular deaths and recurrent heart issues, positively impacting Alnylam's market share, with stock prices rising about 18%. 2. On July 10, analysts pointed out that second-generation therapies like Attruby and Amvuttra performed excellently in treating ATTR-CM patients, further boosting market confidence in Alnylam Pharmaceuticals. Analysts believe that the single use of these new therapies is sufficient to treat the disease, driving stock prices up. 3. On July 9, Alnylam's competitor Ionis Pharmaceuticals' drug trial failed, leading to a significant drop in its stock price. Ionis's drug failed to meet expected goals, with stock prices falling 21.8%, positively impacting Alnylam's market competitiveness. The pharmaceutical industry has performed strongly recently, with noticeable capital inflow. Ionis Pharmaceuticals down 8.80%. Based on recent key news: 1. On July 10, Ionis Pharmaceuticals' Phase 3 CARDIO-TTRansform trial did not meet its primary endpoint, leading to a significant drop in stock prices. Although the drug showed risk reduction in the monotherapy subgroup, the overall results disappointed the market. The law firms SueWallSt and Levi & Korsinsky have notified investors that they are investigating potential violations of securities laws, focusing on whether the CEO's previous statements about the trial's success constituted significant misrepresentation. 2. On July 9, Ionis Pharmaceuticals' eplontersen, developed in collaboration with AstraZeneca, failed to meet the primary efficacy endpoint in the Phase 3 study for the ATTR-CM indication, leading to a pre-market drop of over 21% The drug did not significantly reduce cardiovascular risk in patients on a standard stabilizer treatment, but secondary endpoints and safety performance remained good. 3. On July 10, TD Cowen analysts maintained a buy rating but lowered the target price from $108 to $94, believing that despite the trial setbacks, Wainua still has independent value and a strong pipeline. The overall industry performance is weak, with increasing macroeconomic uncertainty. **Stocks ranked at the top of the industry market capitalization** Amgen fell 0.38%, with increased trading volume. Based on recent key news: 1. On July 8, Amgen signed a memorandum of cooperation with the Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Center, aiming to enhance medical capabilities in Hong Kong and the Greater Bay Area. This cooperation is expected to enhance Amgen's market influence in the region and drive stock price volatility. 2. On July 8, market analysis indicated that Amgen faces short-term resistance, which may affect stock price performance. Nevertheless, the long-term outlook remains optimistic, and investors should pay attention to market dynamics. 3. On July 7, Amgen's annualized return over the past 15 years has outperformed the market by 1.05%, indicating its long-term investment value. This information may attract the attention of long-term investors. The biotechnology industry is accelerating collaboration, and the market is focused ### Related Stocks - [DCOY.US](https://longbridge.com/en/quote/DCOY.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md) - [IONS.US](https://longbridge.com/en/quote/IONS.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) ## Related News & Research - [BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines | ONC Stock News](https://longbridge.com/en/news/297552849.md) - [BUZZ-Street View: Revolution's pancreatic cancer drug nod sparks a 'transformative' era](https://longbridge.com/en/news/297178071.md) - [Elicera Therapeutics says USPTO allows U.S. patent application covering ELC-401 CAR-T candidate](https://longbridge.com/en/news/297286001.md) - [China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial](https://longbridge.com/en/news/297148879.md) - [14:52 ETAPhA Foundation Announces 2026 Pinnacle Award Recipients](https://longbridge.com/en/news/297361032.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**